Effects of Yoga and Relaxation on Stress and Quality of Life

September 28, 2022 updated by: Andreas Michalsen, Charite University, Berlin, Germany

Effects of Yoga and Relaxation on Stress and Quality of Life - a Three-armed Randomized Controlled Study

The aim of this study is to measure the effects of three stress reduction methods on patients with stress and stress associated complaints.

Study Overview

Study Type

Interventional

Enrollment (Actual)

102

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Berlin, Germany, 14109
        • Charité Hochschulambulanz für Naturheilkunde am Immanuel Krankenhaus

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

- stress with at least 4 of 10 points on the Numeric Analogue Scale (NAS) at least 1 month and at least 3 of the following 8 stress symptoms: sleep disorder, inappetence or increased appetite, shoulder neck tension/back pain, tension headache, concentration disorder, exhaustion, nervousness/irritability, stress-associated digestive problems

Exclusion Criteria:

  • serious acute or chronic diseases
  • pregnancy or lactation
  • known serious mental illness
  • immobility or restriction for gymnastics exercises due to orthopaedic, neurological or other medical cause
  • participation in another study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Integrative Yoga
A 12-week "Integrative Yoga" intervention which has meditative and psycho-educational components corresponding to traditional yoga practice.
A 12-week "Integrative Yoga" intervention which has meditative and psycho-educational components corresponding to traditional yoga practice.
ACTIVE_COMPARATOR: Iyengar yoga
A 12-week established, predominantly body-oriented yoga intervention (Iyengar yoga).
A 12-week established, predominantly body-oriented yoga intervention (Iyengar yoga).
ACTIVE_COMPARATOR: Mindfulness
A 12-week mindfulness intervention designed for the healthy handling of stress.
A 12-week mindfulness intervention designed for the healthy handling of stress.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Stress questionnaire (Cohen Perceived Stress Scale, CPSS)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Change from Baseline in the CPSS, range from 0 to 4 in each item. Scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 & 4 = 0) to the positively stated items and then summing across all scale items while higher values meaning a higher grade of perceived stress.
Date of inclusion (baseline), after 12 weeks, after 24 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sociodemographic Measurements
Time Frame: Date of inclusion (baseline)
Age, gender, education level, household income, employment status, marital status, language spoken, complete family history, current and previous illness and co-morbidities, and current medications
Date of inclusion (baseline)
Hospital Anxiety and Depression Scale (HADS)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Assessing full scale, range 0-42, lower score meaning a better outcome
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Mindfulness (Freiburger Fragebogen zur Achtsamkeit, FFA)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Assessing full scale, range 0-56, higher score meaning a better outcome
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Behavioral questions: alcohol consumption
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Number of alcoholic beverages on average per week in the last month
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Behavioral questions: relaxation
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Relaxation behavior on average per week in the last month in minutes
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Behavioral questions: cigarettes
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Number of cigarettes on average per week in the last month in minutes
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Medical Outcomes Study Short Form Quality of Life (MOS SF-36)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Assessing full scale, range 0-100, higher score meaning a better outcome
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Zerssen symptom list (B-LR and B-LR')
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Assessing full scale, range 20-80, higher score meaning a better outcome
Date of inclusion (baseline), after 12 weeks, after 24 weeks
International Physical Activity Questionnaire (IPAQ)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
MET minutes represent the amount of energy expended carrying out physical activity. To get a continuous variable score from the IPAQ (MET minutes a week) we will consider walking to be 3.3 METS, moderate physical activity to be 4 METS and vigorous physical activity to be 8 METS.
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Maslach Burnout Inventory (MBI)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Assessing full scale, range 0-96, higher score meaning a better outcome
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Aspects of Spirituality (ASP)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Assessing full scale, range 0-112, higher score meaning a better outcome
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Self-Regulation
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Assessing full scale, range 16-96, higher score meaning a better outcome
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Multidimensional Assessment of Interoceptive Awareness (MAIA)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Assessing full scale, range 0-160, higher score meaning a better outcome
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Trauma symptoms (Posttraumatic Checklist, PCL-5)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Assessing full scale, range 0-80, higher score meaning a better outcome
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Mysticism Scale Short Form
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Assessing full scale, range 0-32, higher score meaning a better outcome
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Numerical Analog Scales
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Assessing stress, back pain, headache, shoulder/neck tension, sleep quality, exhaustion, nervousness, digestive complaints, mood on 0-11 points each.
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Expectation questions
Time Frame: Date of inclusion (baseline)
For intervention 1, intervention 2 and intervention 3 on a 6-point likert scale from 1 (very strong) to 6 (nothing at all)
Date of inclusion (baseline)
Evaluation questions
Time Frame: After 12 weeks, after 24 weeks
For intervention 1, intervention 2 and intervention 3 on a 6-point likert scale from 1 (very strong) to 6 (nothing at all)
After 12 weeks, after 24 weeks
Bio-electrical Impedance Analysis (BIA)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Estimation of the body composition via bio-electrical impedance analysis (muscle mass in kg)
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Dietary Behaviour assessed by Food Frequency Questionaire (Gesundheit Erwachsener in Deutschland, DEGS)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Quantitative description of nutritional habits
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Medication intake
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Name of medication and dosage
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Heart Rate Variability (HRV)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
24h measuring by Faros 180 (chest)
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Electrodermal Activity (Galvanic Skin Response)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
24h measuring by Biovotion Everion device
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Blood Volume Pulse
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
24h measuring by Biovotion Everion device
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Respiration Rate
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
24h measuring by Biovotion Everion device
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Interbeat Interval (IBI)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
24h measuring by Biovotion Everion device
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Heart Rate (HR)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
24h measuring by Faros 180 (chest), Biovotion Everion
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Skin Temperature
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
24h measuring by Biovotion Everion device
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Blood Oxygenization
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
24h measuring by Biovotion Everion device
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Body weight (kg)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
24h measuring by Biovotion Everion device
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Body Mass Index (kg/m2)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Waist circumference (cm)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Date of inclusion (baseline), after 12 weeks, after 24 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Qualitative interviews in focus groups interviews
Time Frame: 12 weeks after inclusion
Qualitative assessment will be carried out in 45-minute focus group interviews in 12 (randomized selected) patients participating in the study. The interviews will be recorded, transcribed and analyzed with qualitative content analysis.
12 weeks after inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

July 29, 2019

Primary Completion (ACTUAL)

January 21, 2021

Study Completion (ACTUAL)

June 30, 2021

Study Registration Dates

First Submitted

July 28, 2019

First Submitted That Met QC Criteria

July 28, 2019

First Posted (ACTUAL)

July 31, 2019

Study Record Updates

Last Update Posted (ACTUAL)

September 29, 2022

Last Update Submitted That Met QC Criteria

September 28, 2022

Last Verified

September 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RELAx

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stress, Psychological

Clinical Trials on Integrative Yoga

3
Subscribe